Nanotechnology offers new solutions for the development of cancer therapeutics that display
improved efficacy and safety. Although several nanotherapeutics have received clinical …

The dependency of the growth of tumors on blood vessels, once considered a doubtful
proposition, has become a major avenue of research and drug development. This review …

Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other
disorders, including age-related macular degeneration. Major progress towards a treatment …

Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer
models, and several in clinical trials. Here we report that angiogenesis inhibitors targeting …

Thrombospondins TSP-1 and TSP-2 are potent endogenous inhibitors of angiogenesis.
They inhibit angiogenesis through direct effects on endothelial cell migration, proliferation …

Angiogenesis inhibitors for the treatment of cancer have now been approved by the Food
and Drug Administration in the United States, and in 28 other countries including China …

Thrombospondins are evolutionarily conserved, calcium-binding glycoproteins that undergo
transient or longer-term interactions with other extracellular matrix components. They share …

In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches
have yielded survival benefit in patients with metastatic cancer. In one approach, the …

Tumour angiogenesis is a fast growing domain in tumour biology. Many growth factors and
mechanisms have been unravelled. For almost 30 years, the sprouting of new vessels out of …

Cancer is not a solo performance, but rather an ensemble pro duction. Tumor cells play the
leading villains, with a diverse sup porting cast of normal cells that can be recruited to aid …